Roth Capital Initiates Coverage On Nuo Therapeutics with Buy Rating, Announces Price Target of $3

Benzinga · 1d ago
Roth Capital analyst Kyle Bauser initiates coverage on Nuo Therapeutics (OTC:AURX) with a Buy rating and announces Price Target of $3.